Chiasma Company Profile (NASDAQ:CHMA)

About Chiasma (NASDAQ:CHMA)

Chiasma logoChiasma, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing oral forms of therapies that are available only by injection. Using its Transient Permeability Enhancer (TPE) technology platform, the Company is developing oral therapies. The Company has completed a Phase III clinical trial of its TPE platform-based product candidate, oral octreotide capsules (trade named as MYCAPSSA) for the treatment of acromegaly, a condition that results in the body's production of excess growth hormone. Octreotide is an analog of somatostatin, a natural inhibitor of growth hormone secretion. The Company is developing octreotide capsules as a liquid-filled solid gelatin capsule formulation, which is intended to be taken over twice a day. The Company's TPE technology enhances the absorption through the intestinal wall of drugs. The Company also focuses on developing CH2 for Orphan indication.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:CHMA
  • CUSIP: N/A
  • Web: www.chiasmapharma.com
Capitalization:
  • Market Cap: $36.54 million
  • Outstanding Shares: 24,359,000
Average Prices:
  • 50 Day Moving Avg: $1.56
  • 200 Day Moving Avg: $1.79
  • 52 Week Range: $1.45 - $3.71
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -1.06
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $3.26 per share
  • Price / Book: 0.46
Profitability:
  • EBIDTA: ($42,610,000.00)
  • Return on Equity: -51.99%
  • Return on Assets: -46.38%
Debt:
  • Current Ratio: 11.80%
  • Quick Ratio: 11.80%
Misc:
  • Average Volume: 56,130 shs.
  • Beta: 1.72
  • Short Ratio: 16.91
 

Frequently Asked Questions for Chiasma (NASDAQ:CHMA)

What is Chiasma's stock symbol?

Chiasma trades on the NASDAQ under the ticker symbol "CHMA."

How were Chiasma's earnings last quarter?

Chiasma Inc (NASDAQ:CHMA) announced its earnings results on Friday, May, 5th. The company reported ($0.29) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.06. View Chiasma's Earnings History.

Who are some of Chiasma's key competitors?

Who are Chiasma's key executives?

Chiasma's management team includes the folowing people:

  • David M. Stack, Independent Chairman of the Board
  • Mark J. Fitzpatrick, President, Chief Executive Officer, Chief Financial Officer, Treasurer, Secretary, Director
  • Drew Enamait, Principal Accounting Officer, Vice President - Finance & Administration, Corporate Controller
  • Roni Mamluk Ph.D., Chief Development Officer
  • Todd Foley, Independent Director
  • Bard J. Geesaman M.D. Ph.D., Independent Director
  • Scott Minick, Independent Director
  • John A. Scarlett M.D., Independent Director
  • John F. Thero CPA, Independent Director

When did Chiasma IPO?

(CHMA) raised $76 million in an initial public offering (IPO) on Thursday, July 16th 2015. The company issued 5,400,000 shares at $13.00-$15.00 per share. Barclays and Cowen and Company served as the underwriters for the IPO and William Blair and Oppenheimer & Co. were co-managers.

Who owns Chiasma stock?

Chiasma's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (13.09%), Vanguard Group Inc. (1.31%) and Morgan Stanley (0.53%). View Institutional Ownership Trends for Chiasma.

Who bought Chiasma stock? Who is buying Chiasma stock?

Chiasma's stock was purchased by a variety of institutional investors in the last quarter, including Vanguard Group Inc. and Morgan Stanley. View Insider Buying and Selling for Chiasma.

How do I buy Chiasma stock?

Shares of Chiasma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chiasma's stock price today?

One share of Chiasma stock can currently be purchased for approximately $1.50.


MarketBeat Community Rating for Chiasma (NASDAQ CHMA)
Community Ranking:  2.0 out of 5 ( )
Outperform Votes:  33 (Vote Outperform)
Underperform Votes:  51 (Vote Underperform)
Total Votes:  84
MarketBeat's community ratings are surveys of what our community members think about Chiasma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Chiasma (NASDAQ:CHMA) (?)
Ratings Breakdown: 1 Sell Rating
Consensus Rating:Sell (Score: 1.00)
Consensus Price Target: N/A

Analysts' Ratings History for Chiasma (NASDAQ:CHMA)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
1/17/2017Barclays PLCDowngradeEqual Weight -> UnderweightN/AView Rating Details
5/13/2016Cowen and CompanyReiterated RatingHoldN/AView Rating Details
4/18/2016Oppenheimer Holdings Inc.Reiterated RatingOutperform$43.00 -> $9.00N/AView Rating Details
4/18/2016William BlairDowngradeOutperform -> Market PerformN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Chiasma (NASDAQ:CHMA)
Earnings by Quarter for Chiasma (NASDAQ:CHMA)
Earnings History by Quarter for Chiasma (NASDAQ:CHMA)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/5/2017Q1 2017($0.23)($0.29)ViewN/AView Earnings Details
8/10/2016Q2($0.63)($0.83)ViewListenView Earnings Details
5/11/2016Q1($0.63)($0.71)ViewListenView Earnings Details
3/14/2016Q4($0.53)($0.61)ViewListenView Earnings Details
11/12/2015Q315($0.38)($0.46)ViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chiasma (NASDAQ:CHMA)
Current Year EPS Consensus Estimate: $-0.90 EPS
Next Year EPS Consensus Estimate: $-1.42 EPS

Dividends

Dividend History for Chiasma (NASDAQ:CHMA)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Chiasma (NASDAQ:CHMA)
Insider Ownership Percentage: 3.20%
Institutional Ownership Percentage: 58.35%
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Institutional Ownership by Quarter for Chiasma (NASDAQ:CHMA)
Insider Trades by Quarter for Chiasma (NASDAQ:CHMA)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/21/2015Health Ventures Lp 7-MedMajor ShareholderBuy93,750$16.00$1,500,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Chiasma (NASDAQ:CHMA)
Latest Headlines for Chiasma (NASDAQ:CHMA)
Source:
DateHeadline
americanbankingnews.com logoChiasma Inc (CHMA) Issues Earnings Results
www.americanbankingnews.com - May 8 at 3:36 PM
finance.yahoo.com logoChiasma Reports First Quarter 2017 Results
finance.yahoo.com - May 5 at 4:30 PM
finance.yahoo.com logoChiasma reports 1Q loss
finance.yahoo.com - May 5 at 4:30 PM
americanbankingnews.com logoChiasma (CHMA) Receiving Somewhat Positive Media Coverage, Analysis Shows
www.americanbankingnews.com - April 29 at 2:03 PM
americanbankingnews.com logoChiasma (CHMA) Earns Daily Media Sentiment Score of 0.13
www.americanbankingnews.com - April 25 at 12:40 PM
americanbankingnews.com logoChiasma (CHMA) Receives Daily Media Sentiment Rating of 0.42
www.americanbankingnews.com - April 21 at 2:13 PM
americanbankingnews.com logoChiasma (CHMA) Earning Somewhat Critical News Coverage, Report Finds
www.americanbankingnews.com - April 15 at 11:21 AM
americanbankingnews.com logoShort Interest in Chiasma Inc (CHMA) Drops By 3.0%
www.americanbankingnews.com - April 11 at 7:13 AM
americanbankingnews.com logo Analysts Set $2.50 Target Price for Chiasma Inc (CHMA)
www.americanbankingnews.com - April 4 at 12:46 AM
streetinsider.com logoChiasma (CHMA) Announces Poster Presentation at ENDO - StreetInsider.com
www.streetinsider.com - March 31 at 2:43 AM
streetinsider.com logoChiasma (CHMA) Announces Poster Presentation at ENDO
www.streetinsider.com - March 30 at 9:43 PM
finance.yahoo.com logoChiasma Announces Poster Presentation at ENDO 2017 on Evaluation of Acromegaly Symptoms from the Newly Developed Acromegaly Treatment Satisfaction Questionnaire
finance.yahoo.com - March 30 at 4:43 PM
finance.yahoo.com logoCHIASMA, INC Financials
finance.yahoo.com - March 22 at 3:34 PM
us.rd.yahoo.com logoChiasma Reports Fourth Quarter and Year End 2016 Results
us.rd.yahoo.com - March 16 at 10:37 PM
biz.yahoo.com logoCHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits
us.rd.yahoo.com - March 16 at 10:37 PM
finance.yahoo.com logoChiasma to Present at the Cowen and Company 37th Annual Health Care Conference
finance.yahoo.com - March 1 at 11:29 AM
finance.yahoo.com logoChiasma downgraded by Barclays
finance.yahoo.com - January 17 at 5:04 PM
us.rd.yahoo.com logoChiasma Provides Year-End Corporate Update and Preliminary Outlook for 2017
us.rd.yahoo.com - January 9 at 5:25 PM
us.rd.yahoo.com logo8:14 am Chiasma reviews 2016, provides preliminary outlook for 2017
us.rd.yahoo.com - January 9 at 5:25 PM
biz.yahoo.com logoCHIASMA, INC Files SEC form 8-K, Results of Operations and Financial Condition, Other Events, Financial Statements an
biz.yahoo.com - January 9 at 5:25 PM
finance.yahoo.com logoChiasma (CHMA) Shares March Higher, Can It Continue?
finance.yahoo.com - January 6 at 4:41 PM
finance.yahoo.com logo3:16 pm Chiasma: FDA states that Octreotide capsules are misbranded; requests Chiasma submit written response letter by January 6
finance.yahoo.com - December 27 at 4:33 PM

Social

Chart

Chiasma (CHMA) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff